Virtu Financial LLC Takes $674,000 Position in Altimmune, Inc. (NASDAQ:ALT)

Virtu Financial LLC bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT) during the third quarter, Holdings Channel.com reports. The fund bought 109,759 shares of the company’s stock, valued at approximately $674,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after acquiring an additional 75,064 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Altimmune by 27.5% during the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock worth $1,211,000 after purchasing an additional 42,553 shares in the last quarter. Stifel Financial Corp increased its holdings in Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after buying an additional 7,746 shares during the last quarter. Finally, Centiva Capital LP acquired a new stake in Altimmune in the third quarter valued at $120,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target on the stock. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Stock Performance

Altimmune stock opened at $9.03 on Friday. The company has a market capitalization of $642.26 million, a P/E ratio of -5.83 and a beta of 0.15. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The stock has a 50-day simple moving average of $7.71 and a 200-day simple moving average of $7.06.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the prior year, the firm posted ($0.39) EPS. As a group, analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.